A Published Patent Application Is IPR Prior Art as of Its Filing Date
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Written by: Brianne M. Kingery and Daniel P. Hughes
LYNK LABS, INC. v. SAMSUNG ELECTRONICS CO., LTD.
Before Lourie, Prost, and Stark
Summary: In an IPR, a patent application is considered a “printed publication” as of the application’s filing date, not its publication date.
Samsung filed a petition for IPR of a Lynk Labs patent, challenging various claims as obvious. Several of Samsung’s asserted grounds of unpatentability relied on a patent application which was filed before, but published after, Lynk Labs’ priority date. Lynk Labs argued that an IPR can only be instituted based on prior art “printed publications,” and that the reference was not a “printed publication” in the prior-art period because it published afterward. The Patent Trial and Appeal Board found the challenged claims unpatentable for obviousness based on the published patent application reference. Lynk Labs appealed.
The Federal Circuit affirmed. The court noted the parties agreed the published patent application reference was a printed publication and was thus a type of reference that can be used as the basis of an IPR challenge under 35 U.S.C. § 311(b). The Federal Circuit further noted that, under 35 U.S.C. § 102(e)(1), a published patent application is deemed prior art as of its filing date. The court held that reading these two provisions together, in an IPR, a published patent application can be deemed a printed publication as of its filing date.
Editor: Sean Murray
More insights
Fresh From the Bench: Latest Precedential Patent Case
Ridge Corp. et al. v. Kirk NationaLease Co. et al. , Appeal No. 2025-1254 (Fed. Cir. July 13, 2026) In its only precedential patent opinion last week, the Federal Circuit considered an appeal of a preliminary injunction issued by the U.S. District Court…
Fresh From the Bench: Latest Precedential Patent Cases
CASE OF THE WEEK Wyeth LLC v. AstraZeneca Pharmaceuticals LP , Appeal No. 2024-2325 (Fed. Cir. July 9, 2026) In our Case of the Week, the Federal Circuit affirmed a district court ruling reversing a $107.5 million jury verdict against AstraZeneca in a case…
Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026)
CASE OF THE WEEK Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026) In our Case of the Week, the Federal Circuit affirmed summary judgment invalidating all claims of Enanta’s Patent No. 11,358,953 as…